Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01500187 · ClinicalTrials.gov registry record · NA

Fluoride Varnish for Treatment of White Spot Lesions

A NA study of White Spot Lesions, sponsored by Solventum US.

Completed
Registry status
NA
Development phase
38
Enrollment target
1
Study location

NCT01500187: Completed NA study of White Spot Lesions, sponsored by Solventum US.

NCT01500187 is a NA study of White Spot Lesions that has completed, run by Solventum US. The registered enrollment target is 38 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01500187, a NA study of White Spot Lesions, has completed, sponsored by Solventum US.

COMPLETED
Registry status
NA
Development phase
38 participants
Enrollment target
1
Study location

Study Summary

Study will look at ability of fluoride varnish to remineralize white spot enamel lesions that can occur around the edge of fixed orthodontic brackets.

Primary Outcome

Outcome of fluoride varnish or gel application to white spot lesions as measured by DIAGNOdent device after orthodontic debonding. Values shown represent the mean DIAGNOdent reading. The DIAGNOdent scale spans values from 0 to 30+ where larger values indicate higher levels of demineralization.

Conditions Studied

Interventions

  • DEVICE Vanish Varnish
  • DEVICE Pediagel

Study Locations (1)

Tennessee

  • College of Dentistry - Memphis

Trial Details

FieldValue
Enrollment Target 38 participants
Start Date 2012-02
Est. Completion 2014-03-31
Phase NA
Solventum US

41 total trials

What the finished NCT01500187 record still lists

NCT01500187 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 1 condition, with White Spot Lesions appearing as the primary indexed condition, and to 2 interventions - of which Vanish Varnish is the first listed.

NCT01500187 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT01500187 about?

NCT01500187 is a clinical study titled "Fluoride Varnish for Treatment of White Spot Lesions". Study will look at ability of fluoride varnish to remineralize white spot enamel lesions that can occur around the edge of fixed orthodontic brackets.

What is the current status of trial NCT01500187?

This trial is currently completed. It is a NA study. The enrollment target is 38 participants. The study started on 2012-02. Estimated completion is 2014-03-31.

What conditions does trial NCT01500187 study?

This clinical trial studies the following conditions: White Spot Lesions.

What interventions are being tested in trial NCT01500187?

The interventions under investigation include: Vanish Varnish (DEVICE), Pediagel (DEVICE).

Who is sponsoring clinical trial NCT01500187?

This trial is sponsored by Solventum US, which has 41 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01500187 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for White Spot Lesions

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01500187's enrollment target sits among peer trials

38 1538th of 2000 higher than 461 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01684904 · 38 participants · NA

    Proton Therapy for Esophageal Cancer

  • NCT03310879 · 38 participants · Phase 2

    Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6

  • NCT03896269 · 38 participants · Phase 1

    CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

  • NCT04085315 · 38 participants · Phase 1

    Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01500187, the US trial registry maintained by the National Library of Medicine. NCT01500187 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.